AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
BURLINGAME, Calif., April 05, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.
Following are the specifics for Corvus’ two poster presentations:
- Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor
| Authored by Blake A. Scott1, Todd Armstrong2, Elizabeth M. Jaffee2 |
| Affiliations: 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Experimental and Molecular Therapeutics |
| Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1 |
- The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1
| Authored by Stephen Willingham1, Po Y. Ho1, Robert Leone2, Emily Piccione1, Carmen Choy1, Andrew Hotson1, Joseph Buggy1, Jonathan Powell2, Richard Miller1 |
| Affiliations: 1Corvus Pharmaceuticals, Burlingame, Calif.; 2Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21 |
The following oral presentation will take place as follows:
- Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy
| Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell |
| Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM |
| Location: Morial Convention Center, New Orleans Theater C |
To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.
ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer [email protected] 650-900-4522 MEDIA CONTACT: Julie Normart, W2O Group 415-946-1087 [email protected]
